Document is current
Any future updates will be listed below
-
Authors
Lyu, Young Sang https://orcid.org/0000-0002-5929-1215
Hong, Sangmo https://orcid.org/0000-0004-0570-3514
Lee, Si Eun https://orcid.org/0000-0001-6086-9814
Cho, Bo Young https://orcid.org/0000-0002-8422-9966
Park, Cheol-Young https://orcid.org/0000-0002-9415-9965
-
Funding
Funding for this research was provided by:
Daewoong Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 6 January 2024
Accepted: 5 February 2024
First Online: 15 February 2024
Declarations
:
: The two phase III trials were conducted according to the concepts outlined in the Declaration of Helsinki, complied with good clinical practice standards, and were approved by both the Korean Ministry of Food and Drug Safety and the Institutional Review Board of each participating hospital. De-identified and anonymized individual patient data were shared among the datasets.
: Not applicable.
: S.E.L., and B.Y.C. are full-time employees of Daewoong Pharmaceutical Co. Ltd. No other potential conflicts of interest relevant to this article were reported.
